ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1190

The Synergistic Effects Of Metabolic Syndrome Indicators and Hyperuricemia In Contributing To Cardiac Event Risk: A Cross-Sectional Examination Of The Nhanes III Data

Daniel A. Albert1,2 and Sayyad Kyazimzade3, 1Medicine/Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 2Rheumatology, The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, 3The Dartmouth Institute for Health Policy & Clinical Practice, Lebanon, NH, Lebanon, NH

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, gout, hyperuricemia and metabolic syndrome

  • Tweet
  • Email
  • Print
Session Information

Title: Metabolic and Crystal Arthropathies II

Session Type: Abstract Submissions (ACR)

Background/Purpose: The focus of this project is to assess the contribution of hyperuricemia and gout to the risk for cardiovascular events. In a preliminary analysis we examined known characteristics of the metabolic syndrome in vascular events. Of the five metabolic syndrome indicators, hypertension, hyperglycemia, dyslipidemia, obesity and elevated triglycerides, each has been shown to increase the risk for experiencing cardiac events (heart attack or stroke). There has yet to be an investigation, however, assessing whether or not these indicators are additive or synergistic in their contribution to the risk for experiencing a cardiac event and their relationship to hyperuricemia and gout.

Methods: Using the NHANES III data set (1988-1994), we conducted a cross-sectional analysis to assess whether or not the five facets of the metabolic syndrome are additive or synergistic in contributing to the risk for experiencing a cardiac event (defined as either a heart attack or stroke). To do so, we used interaction terms in a multiple logistic regression model, controlling for age, sex, race/ethnicity, education, smoking status, exercise, gout diagnosis and serum uric acid levels. Synergy was assessed based on statistical significance of interaction term odds ratios (ORs).

Results: Among all of the interaction terms, only the interaction between all five metabolic syndrome facets was statistically significant (OR = 240.06, 95% CI: 1.73; 33,304.89, p = 0.030), indicative of a synergistic effect.  All other ORs had p-values ≥ 0.060. It is important to note that both ORs for the interaction terms of four of the five indicators had p-values of 0.060 and 0.067, while all other ORs were > 0.1. In this dataset hyperuricemia and gout did contribute additional risk (Hyperuricemia OR 1.11), p-value:0.036, 95%, CI: 1.01, 2.22. Gout OR 2.20 (p-value:0.001, 95% CI: 1.39, 3.49).

Conclusion: Of the five metabolic syndrome indicators, contribution to the risk of experiencing a cardiac event is predominantly additive. Only once a patient acquires four or five of the indicators, does a synergistic relationship begin to become evident in contributing to the odds of experiencing a cardiac event. Hyperuricemia and gout contribute additional risk. Further investigation will examine the interaction between hyperuricemia, gout, and the other components of the metabolic syndrome.


Disclosure:

D. A. Albert,
None;

S. Kyazimzade,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-synergistic-effects-of-metabolic-syndrome-indicators-and-hyperuricemia-in-contributing-to-cardiac-event-risk-a-cross-sectional-examination-of-the-nhanes-iii-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology